Head-to-head · WeighScore
Mint Med vs Ondra Health
By GLP-1 ScorecardUpdated
Score comparison
Ondra Health has the higher recorded score — 86.8/100 to 78.7/100.
Ondra Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Ondra publishes monthly and prepaid compounded injection plans with pharmacy choices; compare the upfront bill, eligible pharmacy and early-cancellation repricing before choosing a term.
Before you choose
Mint Med does not publish a semaglutide price, so its Mint Med review sets out what it does disclose, while the Ondra Health review explains the conditions attached to Ondra Health's figure. The semaglutide cost page compares published rates across the field. Ask Mint Med for a written total before treating either one as the cheaper choice.
If neither one fits, Mint Med vs Pomegranate Health and Mirabel Meds vs Ondra Health compare each of them with another graded program, and the list of alternatives to Mint Med ranks the programs closest to Mint Med on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
Of the sellers that pay us a commission, the yourEra review covers one graded close to these two, at 83.8/100. That relationship never changes a grade, and the review lists what we could not verify.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Mint Med | Ondra Health |
|---|---|---|
| WeighScore | 78.7/100 | 86.8/100 |
| Grade | C+ | B |
| Site position | #44 | #5 |
| Semaglutide | Product and catalog prices conflict; confirm selected plan charge and supply. | $149/mo (compounded; month-to-month) |
| Tirzepatide | Catalog title and starting price differ; confirm selected charge and supply. | $219/mo (compounded; month-to-month) |
| Coverage | Homepage says 35 states but lists 36; confirm treatment-specific eligibility. | Advertises 50 states; pharmacy and formulation eligibility varies |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
FDAWarning letter issued to Glow Medispa, LLC dba Mint Med in June 2026. See the FDA warning-letter database.
Strengths
- Published monthly and prepaid plan choices
- Portal access for treatment questions
What to consider
- Advertised prices conflict
- Processed orders generally final
- Prepaid cancellation can require repricing
- Assigned pharmacy and clinician need confirmation
Strengths
- Publishes monthly charges and separate upfront totals for longer plans
- Allows requests for an eligible pharmacy and formulation, subject to prescribing and availability
- Names independent clinical partners and advertises provider messaging, supplies and shipping
What to consider
- Six- and twelve-month plans require prepayment and an eligible Hallandale or Vials prescription
- Early prepaid cancellation reprices each three-month supply already sent at the regular quarterly rate
- Confirm the selected renewal cutoff and any earned consultation or administrative fees
- Branded and oral access, included lab testing and independent current certification were not established
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.